Skip to main content
Premium Trial:

Request an Annual Quote

Elias Zerhouni, Raynard Kington, Jonathan Dordick, Robert Linhardt

Premium
National Institutes of Health Director Elias Zerhouni said last week that he will resign from his position at the end of October "to pursue writing projects and explore other professional opportunities."
 
Zerhouni said that his departure is timed to synchronize with the end of the current White House administration and that he does not consider the move to be a resignation.
 
Raynard Kington, deputy director of NIH, is expected to serve as acting director until a new White House names his successor.
 

 
Rensselaer Polytechnic Institute last week named Jonathan Dordick, professor of chemical and biological engineering, as director of the Center for Biotechnology and Interdisciplinary Studies. He replaces Robert Linhardt, who has served as acting director since 2007.
 
As director, Dordick plans to use the center to direct faculty and student research toward discoveries “that can be easily translated to actual lifesaving technologies and medicines,” RPI said in a statement.
 
Dordick is the inventor of a biochip that may eliminate the need for animal testing in the chemical and cosmetics industry, and curtail its use in drug discovery. He has co-founded a pair of companies: Solidus Biosciences, a venture-stage biotech company that is further developing the biochip technology; and EnzyMed, a drug-discovery firm.
 
Dordick joined the RPI faculty in 1998, and served as chair of the chemical and biological engineering department for four years. He was also worked as an assistant professor at the University of Iowa. He holds a PhD in biochemical engineering from the Massachusetts Institute of Technology.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.